0a7e0c6f 1254 4654 A3c9 4813093479d6 01
Levetiracetam Tablet, Extended Release
Product Images NDC 68180-118
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68180-118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
0a7e0c6f 1254 4654 A3c9 4813093479d6 02
This appears to be a table of percentages with some numerical values, but it is not clear what the table represents without additional context.*
0a7e0c6f 1254 4654 A3c9 4813093479d6 03
This appears to be a statistical analysis report or a medical study report. It provides results of a study that involved two groups of participants, one receiving immediate-release levetiracetam and the other receiving a placebo. The text also contains percentage values, a pound sign, and some symbols such as * and =. The symbols seem to be used to signify significance levels. Overall, without more information, it is unclear what the study was about or what its findings were.*
0a7e0c6f 1254 4654 A3c9 4813093479d6 04
The text shows a graph with the percentage of patients on the y-axis and certain values on the x-axis. There are two groups portrayed, one represented by 14.4% and the other by 39.4%. The first group is labelled as placebo with a sample size of 104, and there is a symbol indicating there is a statistically significant difference compared to the second group, which is labelled as Immediatomrelease Levetiracetam with a sample size of 180 taking 3000 mg/day.*
0a7e0c6f 1254 4654 A3c9 4813093479d6 05
This appears to be a graph that shows the percentage of patients in a study who experienced certain effects or outcomes based on the medication they were taking: a Placebo (N-97) and an Immediaterelease levetiracetam (N=101). However, it is difficult to discern the exact details and meaning of the data without more context.*
0a7e0c6f 1254 4654 A3c9 4813093479d6 06
0a7e0c6f 1254 4654 A3c9 4813093479d6 07
This is a medication called Levetiracetam, administrated through its extended-release tablets each containing 750 mg USP. The recommended dosage and details on storage are provided on the accompanying prescribing information. Patients are required to receive the medication guide. Manufactured by Lupin Limited in Goa, India, for Lupin Pharmaceuticals in Baltimore, Maryland, USA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
